Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Science

11 Aug 2023

New Study Compares Psychedelics to Hypnosis and Meditation

A new study explores what happens in the brain while under the influence of psychedelics, meditation, and hypnosis....

By Jason Najum

Breaking News

10 Aug 2023

Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program

Christain Angermayer gave some clarification on PCN-101, atai's ketamine program, hinting at new direction for the compound....

By Jason Najum

Industry

2 Aug 2023

Awakn Life Sciences Completes Sale of Clinics; Shifts To Biotech Development

Awakn Life Sciences has sold its last clinic and shifted its focus entirely to its clinical trials and biotech research....

By Jason Najum

Industry

26 Jul 2023

Wonderland Expands: Bringing Together Psychedelics, Mental Health, & Longevity

Microdose’s Wonderland conference is the premier industry event in the psychedelic medicine space - and now it's expanding into mental health and longevity....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Culture

19 Jul 2023

The World’s First Functional Music Record Label: An Interview With Paul Nolan

Microdose Music and Paul Nolan are launching a new psychedelic album and functional music record label....

By Jason Najum

Law & Politics

12 Jul 2023

Police Raid Montreal Mushroom Dispensary on Opening Day

Montreal police raid leads to 4 arrests on opening day of Quebec's first magic mushroom shop...

By Jason Najum

Law & Politics

11 Jul 2023

Australia Legalizes Psychedelics: Are the US and Canada Next?

Australia has legalized psychedelic therapy, could either Canada or the USA be next to legalize medical psilocybin and MDMA?...

By Jason Najum

Finance

4 Jul 2023

The Commercial Market for Legal Psychedelics: Spravato

Spravato provides insights into market potential of legal psychedelics - we take a closer look....

By Jason Najum
psychedelic markets

Finance

29 Jun 2023

Small Pharma Reports 2023 Financial Results & Business Highlights

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights...

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.